Synergic Medical Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Synergic Medical Technologies is pioneering a non-invasive neuromodulation platform targeting the dysfunctional brain networks underlying Parkinson's disease. Founded in 2017, the company is advancing a therapeutic device that has secured FDA Breakthrough Device Designation, indicating significant potential to address an unmet medical need. Operating as a pre-revenue, private entity, Synergic is positioned in the high-growth neurotherapy segment of the medical device sector. Its approach aims to offer a drug-free, potentially home-based alternative to existing invasive treatments like deep brain stimulation.

Parkinson's Disease

Technology Platform

Non-invasive neuromodulation platform targeting dysfunctional brain networks, likely integrating neuroimaging biomarkers for personalized therapy. Platform has potential for applications in drug delivery enhancement.

Opportunities

Large and growing global Parkinson's disease patient population with significant unmet need for effective, non-invasive therapies.

The FDA Breakthrough Device Designation accelerates regulatory pathway and validates clinical potential.

Platform technology allows for expansion into other neurological and psychiatric indications.

Risk Factors

High technical and clinical risk associated with demonstrating efficacy in pivotal trials for non-invasive deep brain modulation.

Future commercial success depends on securing favorable insurance reimbursement.

Competition from both established invasive therapies (DBS) and other emerging non-invasive neuromodulation approaches.

Competitive Landscape

Competes against established invasive Deep Brain Stimulation (DBS) systems from Medtronic, Boston Scientific, and Abbott. Faces emerging competition from other non-invasive neuromodulation companies exploring TMS, tDCS, and focused ultrasound for neurological applications. Must differentiate through superior targeting, personalization, and clinical outcomes.

More companies in Neuroscience & CNS →More companies in United States →